On December 25, there was a transaction on the bulk trading platform of Yiling Pharmaceutical, with a volume of 100000000 shares, with a turnover of 2300000000000000000000000000000000000000000000000 yuan. After further statistics, it was found that in the past 3 months, there have been 8 large transactions in the stock, with a total turnover of 2847480,000 yuan. It can be seen that Yiling's share price may usher in a new "rising period".
In fact, whether the Yiling stock price can be the best has an important relationship with the company's operating conditions. As a listed company with an annual revenue of more than 10 billion yuan, Yiling Pharmaceutical has continuously achieved performance growth on the basis of high base and high growth, and the profit growth rate continues to be higher than the revenue growth rate. From 2019 to 2023, Yiling Pharmaceutical's revenue in the first three quarters increased from 434.7 billion yuan rose to 857.5 billion yuan, revenue nearly doubled;Attributable net profit from 57.4 billion yuan jumped to 175.9 billion yuan, an increase of more than three times. In terms of R&D investment, Yiling Pharmaceutical has also been increasing its efforts, increasing to 6 in the first three quarters of 20234.6 billion yuan, a year-on-year increase of 142%, laying a solid foundation for the growth of Yiling's share price.
Then, Yiling Pharmaceutical has always taken scientific and technological innovation as the core competitiveness of enterprise development, and took the three cores of theory, science and technology, and products as its creed, so as to innovate from the source, combine theory and practice, and finally form an innovative exclusive product system. According to the data, the company has developed and listed more than 10 innovative patented traditional Chinese medicines, covering six types of major diseases with high incidence such as cardiovascular and cerebrovascular diseases, respiratory, endocrine, nerves, tumors, and urology, of which 10 are listed in the national medical insurance catalog and 5 are listed in the national essential drug list, which provides the core driving force for the top of Yiling's stock price.
In the field of drugs for cardiovascular and cerebrovascular diseases, Yiling Pharmaceutical has developed three innovative patented traditional Chinese medicines, Tongxinluo Capsule, Ginseng Song Yangxin Capsule and Qili Qiangxin Capsule, all of which have become the Class A varieties of national medical insurance and the national basic drug catalog, and are widely used in ischemic cardiovascular and cerebrovascular diseases, arrhythmias, chronic heart failure and other diseases, benefiting tens of millions of patients every year. With the frequent academic achievements of cardiovascular and cerebrovascular innovative drugs, the internationalization process of Yiling Pharmaceutical has been accelerated, which has opened up a new increment for Yiling's stock price. On August 25, the evidence-based research results of Qili Qiangxin Capsule and Ginseng Song Yangxin Capsule were released at the 2023 European Society of Cardiology Annual Meeting, showing that the two drugs have a good ** effect on heart failure and atrial fibrillation. On October 24, "China Tongxinluo** Myocardial Protection Study on Acute Myocardial Infarction" related to the world's top medical journal JAMA (Journal of the American Medical Association), impact factor 1207) Publication.
In addition, driven by the continuous expansion of the anti-aging market and the gradual recognition of product value by the market, the terminal sales performance of Yiling Pharmaceutical's Bazi Kidney Supplement Capsule is also outstanding. Zhongkang data shows that Bazi Kidney Supplement Capsule has become a large single product with OTC sales of over 100 million, with the fastest growth and greatest potential among the second-tier varieties, and may become a large variety at the level of 1 billion, providing an important driving force for Yiling's stock price.
It can be seen that whether it is from the market investment trend or the company's operation, it can be seen that the Yiling stock price has long-term investment value. Next, investors are advised to pay close attention to the company's operating conditions and market dynamics in order to make informed investment decisions.
*:Internet. Disclaimer:**The purpose of this article is to convey more information, the content and**copyright belongs to the original author, the views of the article are not the views of this institution, non-commercial use, the content involved is for reference only, does not constitute investment, consumption or behavior advice, if there is ** error or infringement of your legitimate rights and interests, you can contact us by email, we will deal with the deletion as soon as possible. E-mail address: xzbnew@163com